Balimkiz Senman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Balimkiz Senman has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Ann Gage
Department of Cardiovascular Medicine, Centennial Medical Center, Nashville, TN
4 shared publicationsAjar Kochar
Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
2 shared publications- Andrea Elliott
University of Minnesota
2 shared publications - Christopher F. Barnett
Division of Cardiology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA
2 shared publications - David M. Dudzinski
Massachusetts General Hospital
2 shared publications - Israel Safiriyu
Yale School of Medicine
2 shared publications
Latest Publications
- 25 June 2026
- Published by Elsevier in American Heart Journal
- Vol. 301, 107521
The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization
- 25 June 2026
- Published by Elsevier in American Heart Journal
- Vol. 301, 107521
The Society of Critical Care Cardiology—Rationale, blueprint, and lessons learned in the creation of a new multidisciplinary professional organization
- 15 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 728-738
Associations between admission C-reactive protein and in-hospital mortality amongst patients with cardiogenic shock
Aims: Systemic inflammation in cardiogenic shock is associated with increased disease severity and mortality. C-reactive protein (CRP) is a widely accessible inflammatory biomarker that may aid phenotyping and risk stratification. We evaluated the association between admission CRP and in-hospital mortality in patients with cardiogenic shock. Methods and results: Using a multicentre, nationally representative database, we identified adults with a discharge diagnosis of cardiogenic shock from 2015 to 2023 who had CRP measured within 2 days of hospital admission; patients with sepsis were excluded. C-reactive protein was analysed in tertiles. Inverse probability weighting (IPW) was used to assess associations with in-hospital mortality. Secondary outcomes included intensive care unit (ICU) and hospital length of stay and total cost. We identified 26 525 patients; median (interquartile ranges) CRP was 18.4 mg/L (5.0–67.0 mg/L). The in-hospital mortality was 28.7, 32.7, and 42.3% across tertiles 1–3. In-hospital mortality increased by 19% for each 50-unit increase in CRP [odds ratio (OR) 1.19; 95% confidence interval (CI): 1.16–1.21, P < 0.001). After IPW, tertiles 2 and 3 had higher absolute mortality risks compared with tertile 1 by 3.9% (95% CI: 2.4–5.3%) and 12.4% (95% CI: 10.9–13.9%), respectively (both, P < 0.001). Findings were consistent in sensitivity analyses restricted to Day 1 CRP measurement, primary diagnoses of heart failure or myocardial infarction, and among patients requiring early mechanical circulatory support (all, P < 0.05). The median ICU and hospital stay increased significantly across tertiles (all, P < 0.001); total cost was not statistically different. Conclusion: In patients with cardiogenic shock, a readily available biomarker, elevated CRP was associated with higher in-hospital mortality.
- 15 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 728-738
Associations between admission C-reactive protein and in-hospital mortality amongst patients with cardiogenic shock
Aims: Systemic inflammation in cardiogenic shock is associated with increased disease severity and mortality. C-reactive protein (CRP) is a widely accessible inflammatory biomarker that may aid phenotyping and risk stratification. We evaluated the association between admission CRP and in-hospital mortality in patients with cardiogenic shock. Methods and results: Using a multicentre, nationally representative database, we identified adults with a discharge diagnosis of cardiogenic shock from 2015 to 2023 who had CRP measured within 2 days of hospital admission; patients with sepsis were excluded. C-reactive protein was analysed in tertiles. Inverse probability weighting (IPW) was used to assess associations with in-hospital mortality. Secondary outcomes included intensive care unit (ICU) and hospital length of stay and total cost. We identified 26 525 patients; median (interquartile ranges) CRP was 18.4 mg/L (5.0–67.0 mg/L). The in-hospital mortality was 28.7, 32.7, and 42.3% across tertiles 1–3. In-hospital mortality increased by 19% for each 50-unit increase in CRP [odds ratio (OR) 1.19; 95% confidence interval (CI): 1.16–1.21, P < 0.001). After IPW, tertiles 2 and 3 had higher absolute mortality risks compared with tertile 1 by 3.9% (95% CI: 2.4–5.3%) and 12.4% (95% CI: 10.9–13.9%), respectively (both, P < 0.001). Findings were consistent in sensitivity analyses restricted to Day 1 CRP measurement, primary diagnoses of heart failure or myocardial infarction, and among patients requiring early mechanical circulatory support (all, P < 0.05). The median ICU and hospital stay increased significantly across tertiles (all, P < 0.001); total cost was not statistically different. Conclusion: In patients with cardiogenic shock, a readily available biomarker, elevated CRP was associated with higher in-hospital mortality.
- 22 November 2025
- Published by Elsevier in American Heart Journal
- Vol. 293, 107310
Towards an understanding of best practice: The good, the bad and the future of cardiogenic shock teams
- 22 November 2025
- Published by Elsevier in American Heart Journal
- Vol. 293, 107310
Towards an understanding of best practice: The good, the bad and the future of cardiogenic shock teams
- Open Access
- 19 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (6) , e031979
Need for a Cardiogenic Shock Team Collaborative—Promoting a Team‐Based Model of Care to Improve Outcomes and Identify Best Practices
Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time‐sensitive condition that commonly results in cardiovascular complications and multisystem organ failure, necessitating multidisciplinary expertise. Managing patients with cardiogenic shock remains challenging even in well‐resourced settings, and an important subgroup of patients may require cardiac replacement therapy. As a result, the idea of leveraging the collective cognitive and procedural proficiencies of multiple providers in a collaborative, team‐based approach to care (the “shock team”) has been advocated by professional societies and implemented at select high‐volume clinical centers. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes. Although several registries exist that are beginning to inform care, particularly around therapeutic strategies of pharmacologic and mechanical circulatory support, none of these are currently focused on the shock team approach, multispecialty partnership, education, or process improvement. We propose the creation of a Cardiogenic Shock Team Collaborative—akin to the successful Pulmonary Embolism Response Team Consortium—with a goal to promote sharing of care protocols, education of stakeholders, and discovery of how process and performance may influence patient outcomes, quality, resource consumption, and costs of care.
- 19 March 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (6) , e031979
Open AccessNeed for a Cardiogenic Shock Team Collaborative—Promoting a Team‐Based Model of Care to Improve Outcomes and Identify Best Practices
Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. It is a time‐sensitive condition that commonly results in cardiovascular complications and multisystem organ failure, necessitating multidisciplinary expertise. Managing patients with cardiogenic shock remains challenging even in well‐resourced settings, and an important subgroup of patients may require cardiac replacement therapy. As a result, the idea of leveraging the collective cognitive and procedural proficiencies of multiple providers in a collaborative, team‐based approach to care (the “shock team”) has been advocated by professional societies and implemented at select high‐volume clinical centers. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes. Although several registries exist that are beginning to inform care, particularly around therapeutic strategies of pharmacologic and mechanical circulatory support, none of these are currently focused on the shock team approach, multispecialty partnership, education, or process improvement. We propose the creation of a Cardiogenic Shock Team Collaborative—akin to the successful Pulmonary Embolism Response Team Consortium—with a goal to promote sharing of care protocols, education of stakeholders, and discovery of how process and performance may influence patient outcomes, quality, resource consumption, and costs of care.